Article
One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented addressed issues related to these differences particularly in the aspects of treatment response and disease activity.
All News
Dr. John Cush
Tweet
Difficult to Manage Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. #ACR24
https://t.co/5i5QtJJm16 https://t.co/c4bllA8ngJ
Dr. John Cush
Tweet
PREDICT-SpA: Evaluating the influence of gender on disease assessment tools
Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw
sheila
Tweet
Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO
Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO
@RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4
sheila
Tweet
SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study.
Reasons for stopping SEC:
lack of efficacy
pt decision
lost to ffup
AEs
Reassuring data on SECs position in the treatment of PsA/AS.
@Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi
Eric Dein
Tweet
A#2583
Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring
MOSAIC P4 open label trial
Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints
No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation
@RheumNow #ACR24 https://t.co/3GKEGJbtdc
sheila
Tweet
A systematic review & meta-analysis by Dr. JBCorrea et al show that the ff immune-mediated dses are assocd w/⬆️ ocurrence risk after covid19 infection 👇
Behcets
SpA
SS
SLE
PMR
Pso
RA
Sjogrens
T1DM
Vasculitis
IBD
Ask prior covid infexn in pts history
@RheumNow #ACR24 abs2614 https://t.co/TIEglPrmvL
sheila
Tweet
A higher number of axSpA pts enrolled in BE MOBILE 1&2 who were treated with BKZ achieved remission accdg to the OSI vs. ASDAS ID (40.5% vs 15.2%) at wk 16 until wk 52.
OSI a better measure of remission?
@RheumNow #ACR24 abs2362 https://t.co/GCHjXQi9S9
Richard Conway
Tweet
Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf
Dr. John Cush
Tweet
Reproductive Issues in axSpA: Fertility and Pregnancy
axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu
Antoni Chan MD (Prof)
Tweet
Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term.
Key findings:
- AxSpA: 3.7% incidence (1.3/100 PY) with BKZ.
- PsA: Only 0.2% incidence (0.1/100 PY).
- All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e
Akhil Sood MD
Tweet
Food for thought 🤔
Abstract 1900 found non-diet soda and certain supplements (folate, B-vitamins, fish oil) were higher among individuals with incident SpA compared to controls
@RheumNow #ACR24 https://t.co/qUXcxSfTxE
Patricia Harkins
Tweet
Imaging in TAK Diagnosis
@KQuinnRheum @RheumNow
⭐ Take homes ⭐
👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK
👉FDG PET -focal uptake in TAK vs diffuse in GCA
👉MRI good surrogate for disease activity where PET unavailable
#ACR24 https://t.co/UWxTAZScIt
Antoni Chan MD (Prof)
Tweet
A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial
spondyloarthritis axSpA and IBD showed the following:
- TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA
Richard Conway
Tweet
Fantastic interview from @RheumNow from #ACR24 of @DrTrishHarkins talking to @bososhea from @stjamesdublin @tcddublin @TrinityMed1 about carotid doppler ultrasound screening in AxSpA https://t.co/HN1nA5lNTj
David Liew
Tweet
Rheumatic irAEs can get on the CAR-T bandwagon, too!
CAR-T can invoke new rheumatological issues (not just cytokine release) - see @DrGomezPuerta's experience.
Infrequent, but if CAR-T in general becomes common, yet another job for us to attend to...
#ACR24 ABST2004 @RheumNow https://t.co/xBSlhUdkNr
Adela Castro
Tweet
Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO.
There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies.
Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr
Adela Castro
Tweet
SURPASS trial of bio naïve axSpA at risk of radiographic progression:
1. Presence of syndesmophytes
2. Higher CRP levels
3. Higher ASDAS
4. Higher spinal MRI BME scores
Were predictors of spinal progression independent of ttnt
Abst#1759 #ACR24 @RheumNow https://t.co/QC9FMPufPY
sheila
Tweet
Dr. BDinneen et al reported predictors that can help screen axSpA pts w/o traditional CV RFs for carotid doppler utz:
- shorter dse duration
- no family hx of IHD
- HLAB27+
- ⬆️ dBP, WHratio, ferritin, TC, LDL and TC:HDL ratio
Small size, more data reqd
@RheumNow #ACR24 abs1440 https://t.co/3pZxFmutJz
sheila
Tweet
The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al.
axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed
@RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x
